

## REFERENCE

- Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M. and Vardiman, J.W., 2016. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. *Blood*, pp.blood-2016.
- Au, W.Y., Caguioa, P.B., Chuah, C., Hsu, S.C., Jootar, S., Kim, D.W., Kweon, I.Y., O'Neil, W.M., Saikia, T.K. and Wang, J., 2009. Chronic myeloid leukemia in Asia. *International journal of hematology*, 89(1), pp.14-23.
- Bennour, A., Saad, A. and Sennana, H., 2016. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays. *Critical reviews in oncology/hematology*, 97, pp.263-274.
- Bennour, A., Sennana, H., Laatiri, M.A., Khelif, A. and Saad, A., 2008. A masked BCR/ABL rearrangement in a case of chronic myeloid leukemia with translocation t (3; 9)(p14; q34). *Cancer genetics and cytogenetics*, 181(1), pp.72-74.
- Calabretta, B. and Perrotti, D., 2004. The biology of CML blast crisis. *Blood*, 103(11), pp.4010-4022.
- Chang, J.S., Santhanam, R., Trotta, R., Neviani, P., Eiring, A.M., Briercheck, E., Ronchetti, M., Roy, D.C., Calabretta, B., Caligiuri, M.A. and Perrotti, D., 2007. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2-dependent suppression of C/EBP $\alpha$ -driven myeloid differentiation. *Blood*, 110(3), pp.994-1003.
- Cortes, J., Silver, R., Khoury, H. and Kantarjian, H., 2016. *Chronic Myeloid Leukemia: Cancer Network*. [online] Cancernetwork.com. Available at: <http://www.cancernetwork.com/cancer-management/CML/> [Accessed 13 Nov. 2016].
- Cortes, J.E., Saglio, G., Baccarani, M., Kantarjian, H.M., Mayer, J., Boqué, C., Shah, N.P., Chuah, C., Casanova, L., Narayanan, G. and Bradley-Garelik, B., 2014. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). *Blood*, 124(21), pp.152-152.
- De Obaldia, M.E., Bell, J.J., Wang, X., Harly, C., Yashiro-Ohtani, Y., DeLong, J.H., Zlotoff, D.A., Pear, W.S. and Bhandoola, A., 2013. T cell development requires constraint of the myeloid regulator C/EBP-[alpha] by the Notch target and transcriptional repressor Hes1. *Nature immunology*, 14(12), pp.1277-1284.
- Deininger, M.W., Goldman, J.M. and Melo, J.V., 2000. The molecular biology of chronic myeloid leukemia. *Blood*, 96(10), pp.3343-3356.

- Dhanesh, S.B., Subashini, C. and James, J., 2016. Hes1: the maestro in neurogenesis. *Cellular and Molecular Life Sciences*, pp.1-24.
- Elefanty, A.G., Hariharan, I.K. and Cory, S., 1990. Bcr-Abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. *The EMBO journal*, 9(4), p.1069.
- Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R. and Kantarjian, H.M., 1999. The biology of chronic myeloid leukemia. *New England Journal of Medicine*, 341(3), pp.164-172.
- Frazer, R., Irvine, A.E. and McMullin, M.F., 2007. Chronic myeloid leukaemia in the 21st century. *Ulster Medical Journal*, 76(1), p.8.
- Groffen, John, John R. Stephenson, Nora Heisterkamp, Annelies de Klein, Claus R. Bartram, and Gerard Grosveld. "Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22." *Cell* 36, no. 1 (1984): 93-99.
- Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds), 2016. *SEER Cancer Statistics Review, 1975-2013*, National Cancer Institute. Bethesda, MD, [http://seer.cancer.gov/csr/1975\\_2013/](http://seer.cancer.gov/csr/1975_2013/), based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
- Jamieson, C.H., Ailles, L.E., Dylla, S.J., Muijtjens, M., Jones, C., Zehnder, J.L., Gotlib, J., Li, K., Manz, M.G., Keating, A. and Sawyers, C.L., 2004. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. *New England Journal of Medicine*, 351(7), pp.657-667.
- Kageyama, R., Ohtsuka, T. and Kobayashi, T., 2007. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. *Development*, 134(7), pp.1243-1251.
- Kang, Z.J., Liu, Y.F., Xu, L.Z., Long, Z.J., Huang, D., Yang, Y., Liu, B., Feng, J.X., Pan, Y.J., Yan, J.S. and Liu, Q., 2016. The Philadelphia chromosome in leukemogenesis. *Chinese journal of cancer*, 35(1), p.1.
- Kannan, S., Fang, W., Song, G., Mullighan, C.G., Hammitt, R., McMurray, J. and Zweidler-McKay, P.A., 2011. Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression. *Blood*, 117(10), pp.2891-2900.
- Kantarjian, H.M., Keating, M.J., Talpaz, M., Walters, R.S., Smith, T.L., Cork, A., McCredie, K.B. and Freireich, E.J., 1987. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. *The American journal of medicine*, 83(3), pp.445-454.

- Kato, T., Sakata-Yanagimoto, M., Nishikii, H., Ueno, M., Miyake, Y., Yokoyama, Y., Asabe, Y., Kamada, Y., Muto, H., Obara, N. and Suzukawa, K., 2015. Hes1 suppresses acute myeloid leukemia development through FLT3 repression. *Leukemia*, 29(3), pp.576-585.
- Klinakis, A., Lobry, C., Abdel-Wahab, O., Oh, P., Haeno, H., Buonamici, S., van De Walle, I., Cathelin, S., Trimarchi, T., Araldi, E. and Liu, C., 2011. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. *Nature*, 473(7346), pp.230-233.
- Kobayashi, T. and Kageyama, R., 2014. Expression Dynamics and Functions of Hes Factors in Development and Diseases. *Current Topics in Developmental Biology*, pp.263-283.
- Kunisato, A., Chiba, S., Nakagami-Yamaguchi, E., Kumano, K., Saito, T., Masuda, S., Yamaguchi, T., Osawa, M., Kageyama, R., Nakauchi, H. and Nishikawa, M., 2003. HES-1 preserves purified hematopoietic stem cells ex vivo and accumulates side population cells in vivo. *Blood*, 101(5), pp.1777-1783.
- Li, S., Ilaria, R.L., Million, R.P., Daley, G.Q. and Van Etten, R.A., 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. *The Journal of experimental medicine*, 189(9), pp.1399-1412.
- Liu, Z.H., Dai, X.M. and Du, B., 2015. Hes1: a key role in stemness, metastasis and multidrug resistance. *Cancer biology & therapy*, 16(3), pp.353-359.
- Ma, W., Ma, N., Chen, X., Zhang, Y. and Zhang, W., 2015. An overview of chronic myeloid leukemia and its animal models. *Science China Life Sciences*, 58(12), pp.1202-1208.
- Maru, Y., 2001. Molecular biology of chronic myeloid leukemia. *International journal of hematology*, 73(3), pp.308-322.
- McLaughlin, J., Chianese, E. and Witte, O.N., 1987. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. *Proceedings of the National Academy of Sciences*, 84(18), pp.6558-6562.
- Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. *Leuk Lymphoma* 1993; 11 (Suppl. 1): 11-15. [MEDLINE](#)
- Nakahara, F., Kitaura, J., Uchida, T., Nishida, C., Togami, K., Inoue, D., Matsukawa, T., Kagiya, Y., Enomoto, Y., Kawabata, K.C. and Chen-Yi, L., 2014. Hes1 promotes blast crisis in chronic myelogenous leukemia

- through MMP-9 upregulation in leukemic cells. *Blood*, 123(25), pp.3932-3942.
- Nakahara, F., Sakata-Yanagimoto, M., Komeno, Y., Kato, N., Uchida, T., Haraguchi, K., Kumano, K., Harada, Y., Harada, H., Kitaura, J. and Ogawa, S., 2010. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. *Blood*, 115(14), pp.2872-2881.
- Nerlov, C., 2007. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. *Trends in cell biology*, 17(7), pp.318-324..
- Nowell, P.C., Hungerford, D.A., 1960. A minute chromosome in human chronic granulocytic leukemia [abstract]. *Science* 132, 1497.
- Nowicki, M.O., Falinski, R., Koptyra, M., Slupianek, A., Stoklosa, T., Gloc, E., Nieborowska-Skorska, M., Blasiak, J. and Skorski, T., 2004. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. *Blood*, 104(12), pp.3746-3753.
- Nowicki, M.O., Pawlowski, P., Fischer, T., Hess, G., Pawlowski, T. and Skorski, T., 2003. Chronic myelogenous leukemia molecular signature. *Oncogene*, 22(25), pp.3952-3963.
- Pasternak, G., Hochhaus, A., Schultheis, B. and Hehlmann, R., 1998. Chronic myelogenous leukemia: molecular and cellular aspects. *Journal of cancer research and clinical oncology*, 124(12), pp.643-660.
- Perrotti, D., Cesi, V., Trotta, R., Guerzoni, C., Santilli, G., Campbell, K., Iervolino, A., Condorelli, F., Gambacorti-Passerini, C., Caligiuri, M.A. and Calabretta, B., 2002. BCR-ABL suppresses C/EBP $\alpha$  expression through inhibitory action of hnRNP E2. *Nature genetics*, 30(1), pp.48-58.
- Reksodiputro, H., Tadjoeidin, H., Supandiman, I., Acang, N., Kar, A.S., Bakta, M., Benyamin, A.F. and Ashariati, A., 2015. Epidemiology Study and Mutation Profile of Patients with Chronic Myeloid Leukemia (CML) in Indonesia. *Journal of Blood Disorders & Transfusion*, 2015.
- Rowley, J.D., 1973. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* 243, 290–293.
- Santaguida, M., Schepers, K., King, B., Sabnis, A.J., Forsberg, E.C., Attema, J.L., Braun, B.S. and Passequé, E., 2009. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. *Cancer cell*, 15(4), pp 341-352.

- Sessarego, M., Fugazza, G., Bruzzone, R., Ballestrero, A., Miglino, M. and Bacigalupo, A., 2000. Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11. *Haematologica*, 85(1), pp.35-39.
- Shet, A.S., Jahagirdar, B.N. and Verfaillie, C., 2002. Chronic myelogenous leukemia: mechanisms underlying disease progression. *Leukemia*, 16(8), pp.1402-11.
- Siegel, R.L., Miller, K.D. and Jemal, A., 2015. Cancer statistics, 2015. *CA: a cancer journal for clinicians*, 65(1), pp.5-29.
- Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J.K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T.O. and Wasik, M.A., 1997. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. *The EMBO journal*, 16(20), pp.6151-6161.
- Takeda, N., Shibuya, M. and Maru, Y., 1999. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. *Proceedings of the National Academy of Sciences*, 96(1), pp.203-207.
- Tavor, S., Park, D.J., Gery, S., Vuong, P.T., Gombart, A.F. and Koeffler, H.P., 2003. Restoration of C/EBP $\alpha$  expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. *Journal of Biological Chemistry*, 278(52), pp.52651-52659.
- Tybulewicz, V.L., Crawford, C.E., Jackson, P.K., Bronson, R.T. and Mulligan, R.C., 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. *Cell*, 65(7), pp.1153-1163.
- Vardiman, J.W., Harris, N.L. and Brunning, R.D., 2002. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood*, 100(7), pp.2292-2302.
- Voncken, J.W., van Schaick, H., Kaartinen, V., Deemer, K., Coates, T., Landing, B., Pattengale, P., Dorseuil, O., Bokoch, G.M., Groffen, J. and Heisterkamp, N., 1995. Increased neutrophil respiratory burst in bcr-null mutants. *Cell*, 80(5), pp.719-728.
- Wahidin, M., Noviani, R., Hermawan, S., Andriani, V., Ardian, A. and Djarir, H., 2012. Population-based cancer registration in Indonesia. *Asian Pacific Journal of Cancer Prevention*, 13(4), pp.1709-1710.
- Yin, J., Park, G., Lee, J.E., Park, J.Y., Kim, T.H., Kim, Y.J., Lee, S.H., Yoo, H., Kim, J.H. and Park, J.B., 2014. CPEB1 modulates differentiation of glioma stem cells via downregulation of HES1 and SIRT1 expression. *Oncotarget*, 5(16), pp.6756-6769.



Yong, A.S., Szydlo, R.M., Goldman, J.M., Apperley, J.F. and Melo, J.V., 2006. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. *Blood*, 107(1), pp.205-212.